Swiss National Bank Has $7.40 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Swiss National Bank cut its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,600 shares of the company’s stock after selling 1,100 shares during the quarter. Swiss National Bank’s holdings in CRISPR Therapeutics were worth $7,404,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CRSP. Farallon Capital Management LLC acquired a new stake in CRISPR Therapeutics in the 2nd quarter worth $28,625,000. Marshall Wace LLP acquired a new stake in CRISPR Therapeutics in the 2nd quarter worth $10,078,000. Spear Holdings RSC Ltd acquired a new stake in CRISPR Therapeutics in the 1st quarter worth $11,246,000. Private Advisor Group LLC grew its position in CRISPR Therapeutics by 472.9% in the 2nd quarter. Private Advisor Group LLC now owns 77,627 shares of the company’s stock worth $4,193,000 after purchasing an additional 64,076 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after purchasing an additional 46,148 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Trading Up 5.3 %

Shares of NASDAQ CRSP opened at $50.40 on Tuesday. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The company has a market cap of $4.30 billion, a PE ratio of -17.95 and a beta of 1.67. The company has a 50-day moving average of $47.98 and a two-hundred day moving average of $51.73.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the firm posted ($1.41) earnings per share. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.2 earnings per share for the current year.

Wall Street Analyst Weigh In

CRSP has been the topic of several research analyst reports. Truist Financial decreased their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Finally, Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $74.94.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,382 shares of company stock valued at $1,917,679. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.